Etripamil Patent Expiration

Etripamil was first introduced by Milestone Pharmaceuticals Usa Inc in its drug Cardamyst on Dec 12, 2025.

Etripamil Patents

Given below is the list of patents protecting Etripamil, along with the drug name that holds that patent and the company name owning that drug.

Filter patents by

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Cardamyst	US12257224	Methods Of Administration For Highly Water-Soluble Salts Of A Short Acting Phenylalkylamine Calcium Channel Blocker	Jul 15, 2042	Milestone Pharms Usa
Cardamyst	US10117848	Highly Water-Soluble Salts Of A Short Acting Phenylalkylamine Calcium Channel Blocker And Uses Thereof	Apr 13, 2036	Milestone Pharms Usa
Cardamyst	US10010522	Short Acting Phenylalkylamine Calcium Channel Blockers And Uses Thereof	Jun 19, 2028	Milestone Pharms Usa
Cardamyst	US10010523	Short Acting Phenylalkylamine Calcium Channel Blockers And Uses Thereof	Jun 19, 2028	Milestone Pharms Usa
Cardamyst	US9227918	Short Acting Phenylalkylamine Calcium Channel Blockers And Uses Thereof	Jun 19, 2028	Milestone Pharms Usa
Cardamyst	US9463179	Short Acting Phenylalkylamine Calcium Channel Blockers And Uses Thereof	Jun 19, 2028	Milestone Pharms Usa

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List